Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Nefopam hydrochloride 30 mg film-coated tablets

Active Ingredient:
nefopam hydrochloride
Tillomed Laboratories Ltd See contact details
ATC code: 
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 28 Mar 2022
1. Name of the medicinal product

Nefopam hydrochloride 30 mg film-coated tablets

2. Qualitative and quantitative composition

Each film-coated tablet contains 30 mg nefopam hydrochloride.

For the full list of excipients see section 6.1.

3. Pharmaceutical form

Film Coated Tablet

White to off white, round shape, film coated tablets debossed with "EM" on one side and "62" on the other side. The dimensions of the tablet are approximately 7.00 mm x 3.80 mm.

4. Clinical particulars
4.1 Therapeutic indications

Nefopam hydrochlorideis indicated for the relief of acute and chronic pain including post-operative pain, dental pain, musculo-skeletal pain, acute traumatic pain and cancer pain.

4.2 Posology and method of administration



Dosage may range from 1 to 3 tablets three times daily depending on response. The recommended starting dosage is 2 tablets three times daily.

Special population


Older patients may require reduced dosage due to slower metabolism. It is strongly recommended that the starting dose does not exceed one tablet three times daily as older people appear more susceptible to, in particular, the CNS side effects of nefopam hydrochloride and some cases of hallucinations and confusion have been reported in this age group.

Pediatric population

The safety and efficacy of nefopam hydrochloride in children under 12 years has not yet been established. No dosage recommendation can be given for patients under 12 years.

Patients with end-stage renal disease might experience increased serum peak concentrations during treatment with nefopam. In order to avoid that, it is recommended the daily dose should be reduced not only for the elderly, but also for patients with terminal renal insufficiency.

Method of Administration


4.3 Contraindications

Nefopam hydrochloride is contraindicated in patients with a history of convulsive disorders and shouuld not be given to patients taking mono-amine oxidase (MAO) inhibitors. Nefopam hydrochloride is contraindicated in patients with known hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

The side effects of nefopam hydrochloride may be additive to those of other agents with anticholinergic or sympathomimetic activity. It should not be used in the treatment of myocardial infarction since there is no clinical experience in this indication. Hepatic and renal insufficiency may interfere with the metabolism and excretion of nefopam.

Nefopam should be used with caution in patients with angle closure glaucoma. Cases of nefopam dependence and abuse have been reported with nefopam use.

Nefopam hydrochloride should be used with caution in patients with, or at risk of, urinary retention.

Rarely a temporary, harmless pink discolouration of the urine has occurred.

4.5 Interaction with other medicinal products and other forms of interaction

Caution should be exercised when nefopam is administered concurrently with tricyclic antidepressants.

It should be noted that nefopam may interfere with some screening tests for benzodiazepines and opioids. These tests for benzodiazepines and opioids may give false positive results for patients taking nefopam hydrochloride.

4.6 Fertility, pregnancy and lactation

There is no evidence as to the drug safety in human pregnancy, nor is there evidence from animal work that it is free from hazard. Avoid in pregnancy unless there is no safer treatment

4.7 Effects on ability to drive and use machines

Not applicable

4.8 Undesirable effects

Nausea, nervousness, dry mouth and light-headedness, urinary retention, hypotension, syncope, palpitations, gastrointestinal disturbances (including abdominal pain and diarrhoea), dizziness, paraesthesia, convulsions, tremor, confusion, hallucination, angioedema, and allergic reactions may occur. Less frequently, anaphylactic reactions, coma, vomiting, blurred vision, drowsiness, sweating, insomnia, headache and tachycardia have been reported.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme

Website: or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

The clinical pattern of nefopam toxicity in overdose is on the neurological (coma, convulsions, hallucinations and agitation) and cardiovascular systems (tachycardia with a hyperdynamic circulation). Routine supportive measures should be taken and prompt removal of ingested drug by gastric Lavage or induced vomiting with Syrup of Ipecacuanha should be carried out. Oral administration of activated charcoal may help prevent absorption.

Convulsions and hallucinations should be controlled (eg with intravenously or rectally administered diazepam). Beta-adrenergic blockers may help control the cardiovascular complications.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: 4.7.1 Non-opioid analgesics and compound analgesic preparations

ATC code: N02BG06.

Nefopam hydrochloride is a potent and rapidly-acting analgesic. It is totally distinct from other centrally-acting analgesics such as morphine, codeine, pentazocine and propoxyphene.

Unlike the narcotic agents, nefopam hydrochloride has been shown not to cause respiratory depression. There is no evidence from pre-clinical research of habituation occurring with nefopam hydrochloride.

5.2 Pharmacokinetic properties

Nefopam is absorbed from the gastro-intestinal tract. Peak plasma concentrations occur about 1-3 hours after oral administration. About 73% is bound to plasma proteins. It has an elimination half-life of about 4 hours. It is extensively metabolised and excreted mainly in urine. Less than 5% of a dose is excreted unchanged in the urine. About 8% of a dose is excreted via the faeces.

5.3 Preclinical safety data

Not applicable

6. Pharmaceutical particulars
6.1 List of excipients

Tablet Core:

Microcrystalline cellulose,

Pregelatinized starch,

Dicalcium phosphate dihydrate,

Silica colloidal anhydrous,

Magnesium stearate

Tablet Film-coating:


Titanium dioxide (E171),


6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 Years

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Aluminium -PVC/PVDC blister or Aluminium-PVC blister with 30's and 90's tablets

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Tillomed Laboratories Limited

220 Butterfield

Great Marlings, Luton

LU2 8DL, United Kingdom

8. Marketing authorisation number(s)

PL 11311/0686

9. Date of first authorisation/renewal of the authorisation


10. Date of revision of the text


Tillomed Laboratories Ltd
Company image
220 Butterfield, Great Marlings, Luton, LU2 8DL, UK
+44 (0)1480 402 400
+44 (0)1480 402 402
Medical Information Direct Line
+44 (0)1480 402 400
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)1480 402431 / +44 (0)1480 402432
Medical Information Fax
+44 (0)1480 402 402
Stock Availability
+44 (0)1480 402431 / +44 (0)1480 402432